Bayesian modeling for the detection of adverse events underreporting in clinical trials
View ORCID ProfileYves Barmaz, View ORCID ProfileTimothé Ménard
doi: https://doi.org/10.1101/2020.12.18.20245068
Yves Barmaz
1F. Hoffmann-La Roche AG - CH-4070, Basel, Switzerland
PhDTimothé Ménard
1F. Hoffmann-La Roche AG - CH-4070, Basel, Switzerland
PharmD
Article usage
Posted May 12, 2021.
Bayesian modeling for the detection of adverse events underreporting in clinical trials
Yves Barmaz, Timothé Ménard
medRxiv 2020.12.18.20245068; doi: https://doi.org/10.1101/2020.12.18.20245068
Subject Area
Subject Areas
- Addiction Medicine (423)
- Allergy and Immunology (746)
- Anesthesia (218)
- Cardiovascular Medicine (3219)
- Dermatology (270)
- Emergency Medicine (476)
- Epidemiology (13236)
- Forensic Medicine (19)
- Gastroenterology (889)
- Genetic and Genomic Medicine (5057)
- Geriatric Medicine (469)
- Health Economics (772)
- Health Informatics (3180)
- Health Policy (1127)
- Hematology (423)
- HIV/AIDS (999)
- Medical Education (468)
- Medical Ethics (125)
- Nephrology (513)
- Neurology (4802)
- Nursing (254)
- Nutrition (715)
- Oncology (2474)
- Ophthalmology (701)
- Orthopedics (278)
- Otolaryngology (337)
- Pain Medicine (320)
- Palliative Medicine (89)
- Pathology (528)
- Pediatrics (1276)
- Primary Care Research (550)
- Public and Global Health (7364)
- Radiology and Imaging (1668)
- Respiratory Medicine (967)
- Rheumatology (473)
- Sports Medicine (413)
- Surgery (532)
- Toxicology (69)
- Transplantation (231)
- Urology (199)